Liability for Opioid Epidemic
Koskie Minsky LLP in Toronto is pursuing a class action against major pharmaceutical companies on behalf of people in Canada who were prescribed and became addicted to opioids.
The Statement of Claim, issued in the Ontario Superior Court of Justice on May 15, 2019 and recently amended on June 22, 2022, alleges that the manufacturers and distributors of opioids sought to expand the market for, and increase sales of, Opioids by developing a false and misleading new narrative about Opioids. It alleges that the defendants’ campaign promoting the use of opioids for various chronic conditions led to widespread addiction among individuals who were prescribed those medications.
This action comes on the heels of medical findings that opioids are no more effective than NSAIDS at treating many chronic conditions for which they are routinely prescribed. The lawsuit alleges that manufactures knew of this limited efficacy, and the significant risk of addiction, but promoted their products for these uses anyway.
The claim alleges that the defendants made fraudulent misrepresentations, were negligent in their research, development, manufacture, testing, regulatory licencing, distribution, sale and marketing of opioids, and breached the Competition Act. The lawsuit seeks $1.1 billion in damages.